Dec 19 (Reuters) - Vertex Pharmaceuticals Inc said on Thursday that ivacaftor, an experimental drug to treat cystic fibrosis, failed to meet its targeted treatment goal in a late-stage study in people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results